CD22 and breast carcinoma: CD22-mediated B-cell receptor (BCR) regulation, initial triggering of complement, scavenging of heme from plasma, and immunoregulatory interactions between lymphoid–nonlymphoid cell pathways were significantly enriched in low-risk breast cancer.